← Leaderboards
Sung-Yun Pai
Harvard University (Sch Of Public Hlth)
$3,529,457
Attributed
$5,766,638
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3M · FY2005–23$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$10,320,763 · 6
By mechanism
U01$9,028,487 · 2
K08$486,270 · 1
R21$467,178 · 1
R34$258,221 · 1
U54$80,607 · 1
Top collaborators
- Michael A Pulsipher4 shared
Others in their field
Top investigators on “T-Lymphocyte”
- Barton F Haynes · Duke University$296,833,570
- Lawrence Corey · Fred Hutchinson Cancer Center$270,341,865
- Dan H. Barouch · Fred Hutchinson Cancer Center$117,305,894
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$107,651,960
- Alessandro Sette · La Jolla Institute For Immunology$75,756,097
- Rama Rao Amara · Emory University$69,530,112
Research focus
T-LymphocytePhenotypeInfantConditioningB-LymphocytesImmuneCellsBloodCongenital ImmunodeficiencySevere Combined ImmunodeficiencyImmune SystemEngraftmentHematopoietic Stem CellsSamplingAffectClinical TrialsFundingNational Institute Of Allergy And Infectious DiseaseReconstitutionBaseChildAmericanCell PhysiologyAllogenic
Grant awards (20)
Advancing the Diagnosis and Treatment of Rare Primary Immune Disorders$11,672
U54 · FY2023 · AI · contact PI
Advancing the Diagnosis and Treatment of Rare Primary Immune Disorders$10,951
U54 · FY2021 · AI · contact PI
Advancing the Diagnosis and Treatment of Rare Primary Immune Disorders$22,787
U54 · FY2020 · AI · contact PI
Randomized study of low versus moderate dose busulfan in transplant for severe combined immunodeficiency$18,548
U01 · FY2020 · AI
Randomized study of low versus moderate dose busulfan in transplant for severe combined immunodeficiency$1,542,032
U01 · FY2019 · AI
Gene therapy for SCID-X1 with low dose busulfan and a SIN-lentiviral vector$1,404,772
U01 · FY2019 · AI · contact PI
Advancing the Diagnosis and Treatment of Rare Primary Immune Disorders$35,197
U54 · FY2019 · AI · contact PI
Randomized study of low versus moderate dose busulfan in transplant for severe combined immunodeficiency$1,496,446
U01 · FY2018 · AI
Gene therapy for SCID-X1 with low dose busulfan and a SIN-lentiviral vector$1,418,589
U01 · FY2018 · AI · contact PI
Randomized study of low versus moderate dose busulfan in transplant for severe combined immunodeficiency$1,417,336
U01 · FY2017 · AI
Gene therapy for SCID-X1 with low dose busulfan and a SIN-lentiviral vector$598,418
U01 · FY2017 · AI · contact PI
Gene therapy for SCID-X1 with low dose busulfan and a SIN-lentiviral vector$1,132,346
U01 · FY2016 · AI · contact PI
Dose Finding Study of Busulfan for Newly Diagnosed Infants with SCID$258,221
R34 · FY2014 · AI · contact PI
Humanized Mouse Models of Severe Combined Immunodeficiency$254,678
R21 · FY2010 · AI · contact PI
Humanized Mouse Models of Severe Combined Immunodeficiency$212,500
R21 · FY2009 · AI · contact PI
GATA3 in T cell maturation/T helper cell differentiation$125,037
K08 · FY2005 · AI
GATA3 in T cell maturation/T helper cell differentiation$125,037
K08 · FY2004 · AI
GATA3 in T cell maturation/T helper cell differentiation$125,037
K08 · FY2003 · AI
GATA3 in T cell maturation/T helper cell differentiation$84,429
K08 · FY2002 · AI
GATA3 in T cell maturation/T helper cell differentiation$26,730
K08 · FY2002 · AI